|Articles|August 31, 2006

Oxygen Transmitter

The Vaisala Group's (www.vaisala.com/OMT355) SPECTRACAP Oxygen Transmitter OMT355 is a new product for monitoring oxygen in industrial process gases.

The Vaisala Group’s (www.vaisala.com/OMT355) SPECTRACAP Oxygen Transmitter OMT355 is a new product for monitoring oxygen in industrial process gases. The sensor now offers Tunable Diode Laser (TDL) technology in a compact probe suitable for field use. The OMT355 can be flange-mounted directly into a process without sampling, or onto sample conditioning equipment, to provide real-time measurement data without sampling or sample switching delays. The stainless steel probe tolerates aggressive chemicals and high moisture levels.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

The approval lets adults with moderate-to-severe Crohn’s disease start risankizumab-rzaa at home, supported by phase 3 AFFIRM results at week 12. Credit: Stock.Adobe.com/Matthieu

October 23rd, 2026

FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease

The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.

October 23rd, 2026

The BioPharm Brief: Gilead’s Oral IL-23R Bet, Roche’s Trispecific Deal, and Treasury’s Biotech Investment Proposal

Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.

Speaker giving a talk at a corporate business conference. Audience in hall with presenter in front of presentation screen. Corporate executive giving speech during business and entrepreneur seminar. | Image credit: © Right 3 - © Right 3 - stock.adobe.com

October 23rd, 2026

Dr Gerberding to Open AAPS PharmSci 360 on Redesigning Drug Development

FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.

October 23rd, 2026

How Agentic AI Identifies Toxicology Data Gaps and Testing Options

Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.

Doctor with human Colon anatomy model. Colonic disease, Large Intestine, Colorectal cancer, Ulcerative colitis, Diverticulitis, Irritable bowel syndrome, Digestive system and Health concept | Image credit: © Jo Panuwat D - © Jo Panuwat D - stock.adobe.com

October 23rd, 2026

Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion

Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.

3D illustration of a translucent blue human torso showing the skeleton, with pink lungs, trachea, and branching bronchi highlighted in the chest. | Image Credit: © yodiyim - stock.adobe.com

October 23rd, 2026

Zymeworks Licenses DLL3-Targeted Trispecific T-Cell Engager ZW209 to Roche in Deal Worth Up to $813 Million

Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.

Exterior of the US Department of the Treasury building in Washington, DC, with a columned entrance, an American flag on the roof, green shrubs and a lawn in the foreground, and a clear blue sky. | Image Credit: © Jorge Moro - stock.adobe.com

October 23rd, 2026

Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act

A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.

October 23rd, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 2: CMC and Regulations

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.

Oxygen Transmitter

Related to this article

Trending on BioPharm International

Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act

FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease

Zymeworks Licenses DLL3-Targeted Trispecific T-Cell Engager ZW209 to Roche in Deal Worth Up to $813 Million

Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy